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Abstract
Abnormalities in the TP53 gene and overexpression of MDM2, a transcriptional target and 
negative regulator of p53, are commonly observed in cancers. The MDM2-p53 feedback loop 
plays an important role in tumor progression and thus, increased understanding of the pathway has 
the potential to improve clinical outcomes for cancer patients. Hepatocellular carcinoma (HCC) 
has emerged as one of the most commonly diagnosed forms of human cancer; yet, the current 
treatment for HCC is less effective than those used against other cancers. We review the current 
studies of the MDM2-p53 pathway in cancer with a focus on HCC, and specifically discuss the 
impact of p53 mutations along with other alterations of the MDM2-p53 feedback loop in HCC. 
We also discuss the potential diagnostic and prognostic applications of p53 and MDM2 in 
malignant tumors as well as therapeutic avenues that are being developed to target the MDM2-p53 
pathway.
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The increase in cancer burden in the world, from 12.7 million new cases in 2008 to a 
predicted 22.2 million by 2030 (1), makes cancer a critical global problem. Of all human 
cancers, hepatocellular carcinoma (HCC) is the 5th most frequently diagnosed cancer 
worldwide and is the 3rd leading cause of cancer death globally (2). HCC is commonly 
correlated with viral infection (hepatitis B and C), alcohol consumption, and aflatoxin B1 
exposure. Moreover, HCC is often accompanied by cirrhosis and hepatic insufficiency, 
which makes the treatment of HCC more difficult than for many other forms of cancer. 
Currently, surgical resection is the most commonly practiced therapy for HCC.
p53 acts as a tumor suppressor by initiating cell cycle arrest, apoptosis, and senescence in 
response to cellular stress to maintain the integrity of the genome. 50% of overall human 
tumors carry mutant p53, and many p53 mutants facilitate oncogenic functions such as 
increased proliferation, survival, and metastasis or exert a dominant-negative regulation over 
remaining wild-type (WT) p53 (3). p53 is primarily regulated by the E3 ubiquitin ligase 
MDM2 (Murine Double Minute 2; usually denoted as Mdm2 in mice and HDM2 in humans; 
MDM2 is used hereafter for simplicity). MDM2 binds p53 at its transactivation domain 
blocking p53 mediated transcriptional regulation, while simultaneously promoting its 
polyubiquitination and proteasome dependent degradation. Interestingly, p53 enhances 
MDM2 transcription through p53 specific response elements in the promoter region of 
MDM2, thus forming an auto-regulatory feedback loop, which is critical to control the 
balance of p53 and MDM2 (Figure 1). Inhibition of MDM2-p53 binding could reactivate 
p53 in cancer cells with WT p53 and may offer an effective therapeutic approach for 
millions of cancer patients (4). Furthermore, the top two risk factors of HCC are metabolic 
disease (such as fatty liver) and viral infection (such as hepatitis B and C), both of which 
cause cirrhosis prior to HCC (5,6). As one of the hallmarks of cancer (7), the changes 
observed in cancer cell metabolism and bioenergetics are current hotspots in cancer research 
(8), and the ability of p53 to regulate metabolism has also been attracting more attention 
over recent years (9). Therefore, the connection between p53 stress response and the 
disordered metabolic process leading to HCC, as the liver is the primary metabolic organ, is 
a potential avenue for development of targeted therapies against HCC. In this review we 
focus on the role of the MDM2-p53 pathway in HCC, but the basic principles discussed here 
can also be applied to other forms of cancer.
p53 misregulation in hepatocellular carcinoma
p53-mediated apoptosis depends primarily on death stimuli that target the mitochondria 
either directly or indirectly through the pro-apoptotic members of the Bcl-2 family such as 
Bax and Bak, which both exhibit reduced expression in HCC with mutated TP53 (10). 
Interestingly, the normal liver is relatively resistant to p53-mediated cell death, and the link 
between apoptosis and the translocation of p53 to the mitochondria following DNA damage 
is rarely observed (11). In cultured HCC cells, p53 activation preferentially triggers cell 
cycle arrest rather than apoptosis, and the mitochondrial dependent p53 program of 
apoptosis is also often blocked in hepatocytes (12). One potential mechanism responsible for 
this change is that p53 activation results in the enhanced expression of hepatic insulin-like 
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growth factor-binding protein-1 (IGFBP1), which antagonizes the mitochondrial p53 
program and inhibits apoptosis (13). It is clear that p53 plays a role in mitotic fidelity and 
DNA ploidy conservation in hepatocytes of both the normal and regenerative liver. In 
quiescent livers, hepatocytes exhibit higher ploidy levels in the absence of p53, and this 
phenotype is further exaggerated when the tissues undergo regeneration after partial 
hepatectomy (14). p53 not only restricts malignant transformation by triggering a cell-
autonomous program of cell-cycle arrest or apoptosis, but it also does so in a non-cell 
autonomous manner through the release of senescence associated secretory phenotype 
(SASP) to inhibit tumorigenesis by promoting a tumor suppressive microenvironment. 
Ablation of the p53-dependent senescence program in hepatic stellate cells under chronic 
liver damage increases liver fibrosis and cirrhosis, which are associated with reduced 
survival; furthermore, loss of p53 enhances the transformation of adjacent epithelial cells 
into hepatocellular carcinoma (15). In conclusion, p53 plays important and unique roles in 
normal liver cells and HCC, and it is important to further explore the alterations and 
mechanisms behind this regulation.
Alterations in the MDM2-p53 pathway in HCC
Alterations in the MDM2-p53 pathway are common in HCC (16–18), and single base 
substitutions in TP53 occur in approximately 25% of HCC suggesting a relevant role for p53 
in HCC (19). Mutations of TP53 in HCC occur primarily in the DNA binding domain of p53 
resulting in a lower affinity to bind the sequence-specific response elements of its target 
genes, which also decreases p53-mediated induction of MDM2. Consequently, the 
misregulation of MDM2 results in elevated levels of mutant p53 in many tumors cells or 
tissues (20). MDM2-p53 regulation in the liver appears to differ from other tissues as it is 
reported that in MDM2 null mice, liver was the only tissue where accumulation of mutant 
p53 R172H was not detected (21). It is unknown why MDM2 null mice do not express 
mutant p53 (p53R172H) in the liver; however, several possible mechanisms could 
contribute to this effect. First, numerous studies including the study by Terzian et al have 
demonstrated that p53 expression levels in the liver are typically much lower than that of 
other tissues. Tissues such as spleen, thymus, bone marrow and small intestine are 
commonly utilized in the study of mouse p53 because of the readily detectable p53 levels. 
Second, the regulation of p53 by MDM2 may be different in liver tissue compared to other 
tissues. For instance, liver is considered a radiation insensitive tissue compared to other 
tissues, in which radiation induces strong p53 response. It has also been theorized that the 
MDM2-p53 feedback loop functions differently in liver tissue than in other tissues, and this 
difference may contribute to the subdued p53 (or p53R172H in this case) accumulation in 
the absence of MDM2. Furthermore, unlike in other tissues p53 appears to be insensitive to 
the high levels of aneuploidy that accumulate in the liver. Such “abnormal” characteristics 
of p53 make the liver a unique tissue in terms of p53 regulation, and further studies of the 
mechanisms behind this tissue specificity are needed to fully understand the complex role of 
mutant p53 in HCC.
Stresses associated with in vitro or in vivo systems may also affect the feedback control of 
the MDM2-p53 loop and its function. In HCC, this loop can be affected at multiple levels 
(22): (1) frequent p53 mutations occur in aflatoxin-induced HCC (>50%); (2) frequent p53 
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mutations occur in 20–40% of HCC not associated with aflatoxin exposure; (3) micro 
deletions of p14ARF (alternative reading frame product of CDKN2A locus, p19Arf in 
mouse) occur in 15–20% of HCC with WT p53 but rarely occur in HCC with mutant p53; 
(4) increased MDM2 expression has been observed in HCC; (5) the vast majority of HCC 
overexpress gankyrin, which inhibits both retinoblastoma protein (Rb)-checkpoint and p53-
checkpoint functions; (6) WT p53 can be inhibited in trans by p53 mutants under conditions 
of high mutant p53 expression (23). Under normal conditions when key sites in MDM2 and 
p53 are not phosphorylated (24,25), an increase in MDM2 expression leads to the direct 
inhibition of p53 transcriptional activity and facilitates tumorigenic cell growth through the 
evasion of cell-cycle checkpoint control. Specific hotspots in MDM2 and p53 are associated 
with environmental carcinogen exposure and the development of HCC. For example, the 
309T>G polymorphism (single-nucleotide polymorphism (SNP) 309, rs2279744), which is 
located in the intronic p53-responsive promoter of the MDM2 gene, has the effect of 
increasing MDM2 protein levels and has been shown to be associated with the early onset of 
HCC in patients with chronic HCV infection (26). Yoon et al. evaluated the association of 
MDM2 and p53 polymorphisms with the early onset of HCC in Korean patients with 
chronic hepatitis B virus (HBV) infection. This study found that not only is the MDM2 SNP 
309, but also the p53 codon 72 R>P polymorphism is associated with the development of 
HCC in Korean patients with chronic HBV infection (27). Somatic mutations of R>S at the 
third base in codon 249 of p53 have also been shown to relate to HBV hepatitis B infection, 
and exposure to aflatoxin B1 (28). These HCC associated alterations provide potential 
targets for earlier detection of multiple cancers, and more specifically, may also help doctors 
to more accurately diagnose HCC patients in the clinic.
Mechanisms of targeting the MDM2-p53 pathway in HCC
The following section addresses the specific mechanisms that are known to facilitate HCC 
development by altering the MDM2-p53 pathway, which may also be applicable to other 
forms of cancer (Figure 2). Our lab has previously shown that p53 can be stabilized by 
disruption of ribosome biogenesis, as several ribosomal proteins (RPs) that bind to MDM2 
are released from the nucleolus when ribosome biogenesis is inhibited (29). In the 
regenerating rat liver after partial hepatectomy, there is also evidence that a down-regulation 
of rRNA synthesis can stabilize p53 through the inactivation of MDM2-mediated p53 
degradation by the binding of RPs released from the nucleolus (30). Hepatitis B virus X-
protein (HBx), which binds to p53 and localizes it to the cytoplasm, has been shown to play 
an important role in the development of HCC. Doxorubicin treatment has been shown to 
increase p53 levels in cells containing HBx protein; additionally, doxorubicin treatment 
restores p53-mediated transcriptional activity by reducing MDM2 levels and increasing the 
nuclear accumulation of p53 (31). Similarly, inactivation of the tumor suppressor KLF6 has 
been reported to occur in response to hepatitis C virus (HCV) infection and KLF6 
expression has been shown to inversely correlate with HCC prognosis (32). KLF6 is a 
member of the Krüppel-like C2H2 zinc finger family, which has been shown to be involved 
with cell cycle regulation, signal transduction, and cell differentiation. Mirko et al. reported 
that reduced KLF6 expression causes MDM2 to increase along with p53 reduction, and this 
imbalance in the MDM2-p53 pathway is further associated with decreased survival in 
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patients with surgically resected HCC; conversely, overexpression of KLF6 leads to reduced 
MDM2 expression and a corresponding increase in p53 expression in HCC cell lines (33). 
Cho-Rok et al. found that the Enigma LIM domain protein, which is involved in signal 
transduction through protein kinases, can increase MDM2 ubiquitin ligase activity and p53 
degradation (34). Furthermore, Enigma can be stimulated by serum response factor (SRF), 
which is also overexpressed in HCC and leads to further MDM2 stabilization and p53 
degradation (34,35). Min et al. showed that one p53 target gene, phosphatase of regenerating 
liver 1 (PRL-1), that is overexpressed in a variety of cancers through an unknown 
mechanism, strongly down-regulated p53 levels and inhibited p53-mediated apoptosis by 
inducing MDM2 phosphorylation through Akt signaling, which forms another feedback loop 
contributing to HCC development (36). Inhibitor of growth 1 (ING1) has been reported as a 
type II tumor suppressor that affects cell function by altering chromatin structure and 
regulating transcription (37). Zhu et al. found that ING1 acts as a tumor suppressor by 
inhibiting hepatoma cell proliferation through the induction of apoptosis and cell cycle 
arrest. These tumor suppressor functions are likely mediated by two possible mechanisms: 
an increase in p14ARF expression to inhibit MDM2, or an increase in p53 acetylation and 
activation (38). It has been demonstrated that iron status influences p53 activity by down-
regulating MDM2 expression and that this decrease in MDM2 expression plays a protective 
role in HCC development (39). Interestingly, there is a potential feedback loop between p53 
activation and iron concentration because p53 has been shown to contribute to growth arrest 
by reducing iron uptake and intracellular iron concentration through interaction with iron-
responsive element-binding proteins (IRPs) (40). Sirtuin-3 (Sirt3) is a member of the 
mammalian sirtuin family that is localized to the mitochondria and contributes to the control 
of metabolic activity and is further associated with the deregulation of cancer cell 
metabolism, commonly referred to as the Warburg effect (41,42). Sirt3 protein expression is 
shown to be down-regulated in human HCC tissue; furthermore, overexpression of Sirt3 
inhibited HCC cell growth and induced apoptosis in HepG2 and HuH-7 cell lines by up-
regulating p53 protein activity (43). As summarized in Figure 2, the balance between 
MDM2 and p53 is disrupted in HCC. Each of the factors shown performs a unique role in 
facilitating cancer development, but dysfunctional p53 is consistently shown to be the core 
contributor to the development of HCC. More systematic and comprehensive studies are 
needed to provide a better understanding of these mechanisms and other currently unknown 
mechanisms that contribute to HCC development through the manipulation of p53.
Potential of the MDM2-p53 pathway in the diagnosis and prognosis of 
hepatocellular carcinoma
The connections between the MDM2-p53 loop and HCC development suggest that a better 
understanding of this pathway could be a valuable tool for the diagnosis of malignancies or 
prognoses for HCC patients (44). Specifically, serum concentrations of p53 could be a 
convenient and useful non-invasive screening test for HCC. There is a reported correlation 
between high levels of p53 expression in aggressive HCC phenotype to both early 
recurrences of HCC and poor clinical outcomes (45). A case-controlled study demonstrated 
that the levels of anti-p53 antibodies triggered by accumulation of mutant p53 were also 
associated with increased malignancy, which indicates that serum p53 protein levels and 
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antibody concentration may be used as early serological markers in the diagnosis of HCC 
(46–48). Moreover, the levels of p53 and MDM2 in HCC tissue were shown to be 
significantly higher than those in the adjacent hepatic tissues. Zhang et al. demonstrated that 
p53 and MDM2 are overexpressed in all 181 pairs of HCC tissues compared to the adjacent 
hepatic tissues in their study (49). Patients with a low pathologic grade HCC had a higher 
tendency to express p53 in tumor cells than the patients with high pathologic grade HCC; 
similarly, decreased MDM2 expression in HCC was also shown to be a predictor of better 
survival of patients after tumor resection (49). These studies indicate that p53 and MDM2 
expression levels could be useful indicators for predicting the prognosis of HCC. Currently, 
the approaches utilized in the early diagnosis of HCC are limited. The observed alterations 
in the MDM2-p53 pathway may provide more effective and accurate methods to diagnose 
early stage HCC, which would enable earlier surgical resections for patients and 
significantly improve the clinical outcomes even in the absence of a novel targeted therapy 
against the pathway.
Therapeutic avenues of targeting the MDM2-p53 pathway in malignant 
tumors
The critical role of p53 in tumor development and progression has made p53 an exciting 
target for anti-cancer drug design (50). Therapies that focus on restoring p53 function in 
tumors have been shown to be deleterious to cancer cells that express both mutant and WT 
p53 (12). The main strategies for the treatment of these cancers aim to deliver exogenous 
therapeutic WT p53 or to restore WT p53 function from inactivation by using the following 
methods: (1) chemotherapy and radiotherapy, (2) overexpression of ADP-ribosylation factor 
proteins that block p53 degradation pathways, (3) disruption of the MDM2-p53 interaction, 
and (4) introduction of molecules that stabilize the active conformation of the p53 protein 
(51). In order to investigate the importance of the MDM2-p53 loop in radiation-induced cell 
death in HCC, Koom et al. used two HCC cell lines expressing different levels of MDM2 
and two adenoviral vectors containing WT or MDM2 binding deficient human p53. The 
study demonstrated that the anti-tumor effect was the highest for WT p53 plus radiotherapy 
(RT) in the low-level MDM2 cells, whereas the tumor suppressor effect is mimicked by 
overexpressing MDM2 binding deficient p53 in the MDM2-overexpressing cells (52). The 
study also demonstrated that disrupting binding between p53 and MDM2 can effectively kill 
tumor cells that overexpress MDM2. Specifically, exogenous WT p53 induces not only 
apoptosis, but also causes a down regulation of genes involved in angiogenesis, which 
makes tumors more sensitive to chemotherapy (53). Xue et al. used RNA interference 
(RNAi) to conditionally regulate endogenous p53 expression in a mouse model of liver 
carcinoma to determine whether brief reactivation of endogenous p53 in p53-deficient 
tumors can produce complete tumor regression. Interestingly, the primary cellular response 
to p53 reactivation was not apoptosis, but involved the induction of a cellular senescence 
program that was associated with differentiation and the up-regulation of inflammatory 
cytokines (12). This study illustrated how the cellular senescence program can act together 
with the innate immune system to potently limit tumor growth, and also proved p53 loss is 
required for the maintenance of mouse liver carcinomas.
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Activation of WT p53 in tumors through manipulation of the MDM2-p53 pathway could be 
achieved by four main techniques: (1) using mimetics of a negative regulator of MDM2, 
such as p14ARF (54); (2) by reducing MDM2 levels with antisense oligonucleotides or 
small interfering RNA (siRNA) (55); (3) blocking the interaction between MDM2 and p53 
with small molecules, synthetic peptides or monoclonal antibodies; and (4) blocking the 
MDM2-mediated ubiquitination of p53 (56). p14ARF inhibits MDM2-dependent 
degradation and transcriptional silencing of p53; therefore, p14ARF mimetics could be used 
to activate the p53 stress response pathway. Midgley et al. screened a series of overlapping 
synthetic peptides derived from the p14ARF protein and found that a peptide corresponding 
to the first 20 amino acids of p14ARF is sufficient to bind MDM2, which induces p53 
protein stabilization and activates p53-dependent transcriptional regulation (54). MDM2 can 
also be inhibited by antisense anti-MDM2 oligonucleotide and the in vivo antitumor activity 
of such an oligonucleotide occurs in a dose-dependent manner (55). Small molecules that 
disrupt MDM2-p53 interaction such as Nutlin-3, MI series (57,58), benzodiazepinedione 
(59), and RITA (reactivation of p53 and induction of tumor cell apoptosis) (60) can be used 
to treat cancer through increased stabilization of p53. Moreover, MDM2 E3 ubiquitin ligase 
inhibitors such as HLI98 (61), Tenovin-1/Tenovin-6 and JJ78:12 (62) can similarly disrupt 
p53-MDM2 complexes and exert an anti-tumor effect by stabilizing p53 protein. Ribosomal 
proteins, such as L11 and L23, are known to induce p53 by inhibiting MDM2-mediated p53 
degradation (63,64), which suggest that modification of the RP-MDM2-p53 pathway may 
also reduce the proliferation of tumor cells with WT p53. Better systems for the delivery of 
exogenous p53 or small peptides are being developed for more efficient transduction of 
tumor cells. It is expected that some of these small molecules will progress to clinical use, 
alone or in combination with other established therapeutic interventions, and these studies 
will inform the design of novel approaches that specifically target the MDM2-p53 pathway. 
The clinical application of MDM2-p53 modulating drugs is under intense development. 
Safety and efficacy of newly designed drugs capable of modulating either WT or mutant p53 
are now being evaluated.
Future studies and Conclusion
Future studies should focus on the regulation of metabolism by p53 especially in the 
reversible fatty liver stage, which will help to elucidate the central molecular mechanisms at 
this pre-HCC stage and potentially contribute new ideas on how clinicians may be able to 
stifle HCC in its vulnerable early stages. The effect of the MDM2-p53 loop in cancer 
progression is complex, and despite the high number of studies that have already been 
completed, it is clear that a better understanding of tumor cell specific signaling pathways 
that modulate the MDM2-p53 pathway is required for the improvement of clinical 
outcomes. In this review we have summarized the vital roles that the MDM2-p53 pathway 
plays in the development of HCC, the specific mechanisms that are known to facilitate HCC 
development by altering the MDM2-p53 pathway, and the current research initiatives aimed 
at using this knowledge in the clinic. By focusing on HCC, we hope to give a detailed 
account of the molecular mechanisms affecting the MDM2-p53 pathway and the important 
role that balanced MDM2-p53 expression plays in HCC that can be translated to other forms 
of cancers.
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Figure 1. The MDM2-p53 auto-regulatory feedback loop
MDM2 inhibits p53 by stimulating its degradation, blocking its transcriptional activity and 
promoting its nuclear export. In turn, p53 activates the expression of MDM2. DNA-damage 
induces p53 phosphorylation, which prevent the MDM2-p53 binding and leads to p53 
stabilization. Oncogenes such as c-Myc can activate p53 through p14ARF-MDM2-p53 
pathway.
Meng et al. Page 12













Figure 2. MDM2-p53 Pathway alterations in HCC with WT p53
In normal tissues the expression of MDM2 and p53 are balanced; whereas in HCC cells the 
balance is disrupted, where the expression of MDM2 can be high and p53 can be low. This 
imbalance can be attained through the higher expression of SRF, Enigma Lim, HBx and 
PRL-1 in combination with lower expression of KLF6, Sirt3, and ING1. Furthermore, up-
regulation of rRNA synthesis can inhibit p53 due to reduced ribosomal protein availability 
for MDM2 binding. (Larger shapes depict higher expression of the indicated proteins and 
thicker lines depict up-regulation of indicated pathways.)
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